Gut bacteria toxin linked to worse clinical outcomes in patients with alcoholic liver disease; treatment with bacteriophages clears the bacteria and eliminates the disease in mice
Bacteriophages (phages) are viruses that specifically destroy bacteria. In the early 20th century, researchers experimented with phages as a potential method for treating bacterial infections. But then antibiotics emerged and phages fell out of favor. With the rise of antibiotic-resistant infections, however, researchers have renewed their interest in phage therapy. In limited cases, patients with life-threatening multidrug-resistant bacterial infections have been successfully treated with experimental phage therapy after all other alternatives were exhausted.
Researchers at University of California San Diego School of Medicine and their collaborators have now for the first time successfully applied phage therapy in mice for a condition that’s not considered a classic bacterial infection: alcoholic liver disease.
The study publishes November 13, 2019 in Nature.
“We not only linked a specific bacterial toxin to worse clinical outcomes in patients with alcoholic liver disease, we found a way to break that link by precisely editing gut microbiota with phages,” said senior author Bernd Schnabl, MD, professor of medicine and gastroenterology at UC San Diego School of Medicine and director of the National Institutes of Health-funded San Diego Digestive Diseases Research Center.
Up to 75 percent of patients with severe alcoholic hepatitis, the most serious form of alcohol-related liver disease, die within 90 days of diagnosis. The condition is most commonly treated with corticosteroids, but they aren’t highly effective. Early liver transplantation is the only cure, but is only offered at select medical centers to a limited number of patients. In fact, there are only approximately 8,000 liver transplants for all reasons in the United States each year, according to the American Liver Foundation, with a waiting list of roughly 14,000 people.
Alcohol itself can directly damage liver cells. But Schnabl and team had previously discovered that alcohol is also harmful to the liver for a second reason: It diminishes natural gut antibiotics, leaving mice more prone to bacterial growth in the liver and exacerbating alcohol-induced liver disease.
In the current study, Schnabl’s team — including many collaborators around the world — addressed two primary questions: How do gut bacteria contribute to liver damage? And can phages be used to reduce the bacteria and thus alleviate alcoholic liver disease?
The researchers discovered that liver cells are injured by cytolysin, a toxin secreted by Enterococcus faecalis, a type of bacteria typically found in low numbers in the healthy human gut. They also found that people with alcoholic hepatitis have more cytolysin-producing E. faecalis in their guts than healthy people. The more E. faecalis present, the more severe their liver disease. For people with alcoholic liver disease, more than five percent of their fecal bacteria were Enterococcus, compared to almost none in healthy people or people with alcoholic use disorder. Approximately 80 percent of alcoholic hepatitis patients have E. faecalis living in their feces, and 30 percent are positive for cytolysin.
Moreover, the researchers found that nearly 90 percent of cytolysin-positive patients with alcoholic hepatitis died within 180 days of hospital admission, compared to approximately 4 percent of cytolysin-negative patients.
“Based on this finding, we believe detection of the cytolysin-gene in feces from patients with alcoholic hepatitis could be a very good biomarker for liver disease severity and risk of death,” Schnabl said. “One day we might be able to select patients for tailored therapies based on their cytolysin status.”
Next, the team transferred feces from cytolysin-positive and cytolysin-negative people with alcoholic hepatitis to mice. Mice with cytolysin-positive humanized gut microbiomes developed more severe alcohol-induced liver disease and survived less than mice without cytolysin.
To investigate the potential for phage therapy, the researchers isolated from sewage water four different phages that specifically target cytolysin-producing E. faecalis. When they treated the mice with the targeting phages, the bacteria were eradicated and alcohol-induced liver disease was abolished. Control phages that target other bacteria or non-cytolytic E. faecalis had no effect.
“This phage therapy has only so far been tested in mice, and a clinical trial will be required to test the safety of this approach, and validate our findings in patients with alcoholic hepatitis,” Schnabl said.
UC San Diego School of Medicine has been at the forefront of phage therapy development over the past few years. In March 2016, Tom Patterson, PhD, professor of psychiatry at UC San Diego School of Medicine, became the first known person in the United States to successfully undergo intravenous phage therapy for a multidrug resistant bacterial infection, with emergency approval from the U.S. Food and Drug Administration (FDA).
Since then, seven additional patients at UC San Diego Health have been treated with phages. In all cases, the phage treatments were considered experimental and required emergency approval by the FDA. To further advance this work, in June 2018 UC San Diego School of Medicine launched the Center for Innovative Phage Applications and Therapeutics (IPATH), the first such center in North America. Schnabl and study co-authors David Pride, MD, PhD, director of the Clinical Molecular Microbiology Laboratory and associate director of the Microbiology Laboratory at UC San Diego School of Medicine, and Ry Young, PhD, at Texas A&M University, are members of IPATH.
Additional study co-authors include: Yi Duan, Cristina Llorente, Lu Jiang, Samuel B. Ho, UC San Diego and Veterans Affairs San Diego Healthcare System; Sonja Lang, Katharina Brandl, Huikuan Chu, Jinyuan Liu, Yukiko Miyamoto, Melissa Ly, Bei Gao, Weizhong Sun, Roman Kiesel, Felix Hutmacher, Suhan Lee, Xin M. Tu, Lars Eckmann, UC San Diego; Richard C. White, Thomas H. Clarke, Kevin Nguyen, Manolito Torralba, Derrick E. Fouts, J. Craig Venter Institute; Yan Shao, Trevor D. Lawley, Wellcome Sanger Institute; Adriana Hernandez-Morales, Lauren Lessor, Texas A&M University; Imran R. Rahman, University of Illinois at Urbana-Champaign; Meritxell Ventura-Cots, Ramon Bataller, University of Pittsburgh Medical Center, Pittsburgh Liver Research Center; Francisco Bosques-Padilla, Universidad Autonoma de Nuevo Leon; Elizabeth C. Verna, Columbia University; Juan G. Abraldes, University of Alberta; Robert S. Brown Jr, Will Cornell Medical College; Victor Vargas, Universitat Autònoma de Barcelona and Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas; Jose Altamirano, Universitat Autònoma de Barcelona; Juan Caballería, Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas and Liver Unit, Hospital Clinic, Barcelona; Debbie L. Shawcross, King’s College London; Alexandre Louvet, Philippe Mathurin, Hôpital Huriez; Michael R. Lucey, University of Wisconsin; Guadalupe Garcia-Tsao, Yale University and VA-CT Healthcare System; Wilfred A. van der Donk, University of Illinois at Urbana-Champaign and Howard Hughes Medical Institute; and Peter Stärkel, St. Luc University Hospital, Université Catholique de Louvain.
This research was funded, in part, by the National Institutes of Health (grants R01AA24726, U01AA026939, U01AA021908, P30DK120515, P50AA011999, T32GM070421), VA Office of Research and Development (award BX004594), Wellcome Trust (WT098051), DFG Fellowship (LA 4286/1-1) and Biocodex Microbiota Foundation.
Disclosure: Bernd Schnabl is a consultant for Ferring Research Institute.
UC San Diego